Pub Date : 2025-03-17DOI: 10.1016/j.cpccr.2025.100359
Saša Z. Tabaković , Sonja Tabaković
Introduction
Malignant mesenchymal tumors of the salivary glands are neoplasms whose histopathological picture represents a very big diagnostic challenge. Most tumors of the parotid glands are benign, and for malignant neoplasms, immunohistochemistry is essential for diagnosis.
Aim
The aim is to present a rare case of a mesenchymal malignant tumor of the parotid gland, including diagnostics and surgical therapy.
Case presentation
A 67-year-old patient presented with a tumor around the parotid gland. Sonographically, the change resembled an adenoma, although the differential diagnosis did not exclude a pathological entity of another etiology. The patient underwent a superficial parotidectomy, and the operative and postoperative course was without complications. Immunohistochemical analysis in combine with histopath results confirmed the final diagnosis of Clear Cell Sarcoma of the parotid gland.
Conclusion
Clear cell sarcoma of the parotid gland is a rare malignant neoplasm. Timely diagnosis and total parotidectomy with negative resection margins, in the first year after the operation ensure a satisfactory postoperative result without recurrence and meta-changes. Doctors should be very cautious in such situations because the histopathological examination with immunohistochemical analysis gives a clear picture of the tumor in question as a differential diagnosis.
{"title":"Clear cell sarcoma of salivary gland: A case report","authors":"Saša Z. Tabaković , Sonja Tabaković","doi":"10.1016/j.cpccr.2025.100359","DOIUrl":"10.1016/j.cpccr.2025.100359","url":null,"abstract":"<div><h3>Introduction</h3><div>Malignant mesenchymal tumors of the salivary glands are neoplasms whose histopathological picture represents a very big diagnostic challenge. Most tumors of the parotid glands are benign, and for malignant neoplasms, immunohistochemistry is essential for diagnosis.</div></div><div><h3>Aim</h3><div>The aim is to present a rare case of a mesenchymal malignant tumor of the parotid gland, including diagnostics and surgical therapy.</div></div><div><h3>Case presentation</h3><div>A 67-year-old patient presented with a tumor around the parotid gland. Sonographically, the change resembled an adenoma, although the differential diagnosis did not exclude a pathological entity of another etiology. The patient underwent a superficial parotidectomy, and the operative and postoperative course was without complications. Immunohistochemical analysis in combine with histopath results confirmed the final diagnosis of Clear Cell Sarcoma of the parotid gland.</div></div><div><h3>Conclusion</h3><div>Clear cell sarcoma of the parotid gland is a rare malignant neoplasm. Timely diagnosis and total parotidectomy with negative resection margins, in the first year after the operation ensure a satisfactory postoperative result without recurrence and meta-changes. Doctors should be very cautious in such situations because the histopathological examination with immunohistochemical analysis gives a clear picture of the tumor in question as a differential diagnosis.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"18 ","pages":"Article 100359"},"PeriodicalIF":0.2,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143681140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-15DOI: 10.1016/j.cpccr.2025.100363
Sunpil Hwang , Sucheta Kundu , Brett Barlow
Brentuximab Vedotin, an antibody-drug conjugate targeting CD30, has been widely used in treating systemic anaplastic large-cell lymphoma and primary cutaneous anaplastic large-cell lymphoma. Despite its extensive use, information on its use in patients with end-stage renal disease is limited. This case report illustrates a 75-year-old male undergoing daily peritoneal dialysis, diagnosed with primary cutaneous anaplastic large-cell lymphoma. Due to extensive lesions, the patient opted for Brentuximab Vedotin following an exhaustive discussion. Remarkably, the treatment resulted in the complete resolution of cutaneous lesions, which was confirmed by a subsequent negative PET scan, indicating the absence of malignancy. Throughout the treatment course, the patient reported only weakness as a side effect, which was compounded by an acute COVID-19 infection at that time. This case report underscores the potential application of Brentuximab Vedotin in patients undergoing peritoneal dialysis, a population previously excluded, thus providing another promising therapeutic option for this particular population.
{"title":"The successful employment of Brentuximab Vedotin to a patient with peritoneal dialysis: A case report","authors":"Sunpil Hwang , Sucheta Kundu , Brett Barlow","doi":"10.1016/j.cpccr.2025.100363","DOIUrl":"10.1016/j.cpccr.2025.100363","url":null,"abstract":"<div><div>Brentuximab Vedotin, an antibody-drug conjugate targeting CD30, has been widely used in treating systemic anaplastic large-cell lymphoma and primary cutaneous anaplastic large-cell lymphoma. Despite its extensive use, information on its use in patients with end-stage renal disease is limited. This case report illustrates a 75-year-old male undergoing daily peritoneal dialysis, diagnosed with primary cutaneous anaplastic large-cell lymphoma. Due to extensive lesions, the patient opted for Brentuximab Vedotin following an exhaustive discussion. Remarkably, the treatment resulted in the complete resolution of cutaneous lesions, which was confirmed by a subsequent negative PET scan, indicating the absence of malignancy. Throughout the treatment course, the patient reported only weakness as a side effect, which was compounded by an acute COVID-19 infection at that time. This case report underscores the potential application of Brentuximab Vedotin in patients undergoing peritoneal dialysis, a population previously excluded, thus providing another promising therapeutic option for this particular population.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"18 ","pages":"Article 100363"},"PeriodicalIF":0.2,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143681139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-01DOI: 10.1016/j.cpccr.2025.100362
George Bashour , Muhsen Issa , Saddik Haddad , Gabi Kafa , Hussein Kaada , Samer Rajab , Ali Daoud , Rabab Salloum
Background
Primary pulmonary lymphoma (PPL) is a lymphoid proliferation in the lung parenchyma and/or bronchi of a patient with no extrapulmonary lesion within 3 months of diagnosis. Diffuse large B-cell lymphoma (DLBCL) accounts for 10 % of all PPL cases, and only a very minor number of them present with an anaplastic morphologic variant.
Case presentation
We report a 35-year-old female patient who presented with shortness of breath, cough, anorexia, weight loss, fever of unknown origin, and night sweats. The patient was diagnosed with primary pulmonary anaplastic DLBCL and put on rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) regimen. She achieved remission according to the PET scan results; however, the symptoms recurred one year later, and a CT scan confirmed the regrowth of the tumor. The patient refused further chemotherapy and repeated the biopsy at another center, and she was diagnosed with Hodgkin lymphoma and was placed on ifosfamide, carboplatin, and etoposide (ICE) and rituximab, dexamethasone, cytarabine, and cysplatin (RDHAP) protocols for 9 months, which did not improve her condition. Finally, a PET scan revealed that the lesion was limited to the lung with no visible metastases or lymph node involvement, and radical surgery was performed to excise the tumor. A new IHC panel was ordered because of the conflicting reports, and it showed matching results to the first diagnosis, except for a negative CD20 result, which was attributed to rituximab in the patient's chemotherapy. A 2-year follow-up revealed no lesions or recurrence.
Conclusion
DLBCL is an uncommon cause for primary lung lymphomas, but high clinical suspicion must be maintained when assessing such tumors, even among younger individuals. More studies should be done to investigate the best treatment option for the anaplastic variant of DLBCL.
{"title":"Recurrent primary pulmonary anaplastic B-cell lymphoma in a 35-year-old patient treated with radical resection: A case report.","authors":"George Bashour , Muhsen Issa , Saddik Haddad , Gabi Kafa , Hussein Kaada , Samer Rajab , Ali Daoud , Rabab Salloum","doi":"10.1016/j.cpccr.2025.100362","DOIUrl":"10.1016/j.cpccr.2025.100362","url":null,"abstract":"<div><h3>Background</h3><div>Primary pulmonary lymphoma (PPL) is a lymphoid proliferation in the lung parenchyma and/or bronchi of a patient with no extrapulmonary lesion within 3 months of diagnosis. Diffuse large B-cell lymphoma (DLBCL) accounts for 10 % of all PPL cases, and only a very minor number of them present with an anaplastic morphologic variant.</div></div><div><h3>Case presentation</h3><div>We report a 35-year-old female patient who presented with shortness of breath, cough, anorexia, weight loss, fever of unknown origin, and night sweats. The patient was diagnosed with primary pulmonary anaplastic DLBCL and put on rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) regimen. She achieved remission according to the PET scan results; however, the symptoms recurred one year later, and a CT scan confirmed the regrowth of the tumor. The patient refused further chemotherapy and repeated the biopsy at another center, and she was diagnosed with Hodgkin lymphoma and was placed on ifosfamide, carboplatin, and etoposide (ICE) and rituximab, dexamethasone, cytarabine, and cysplatin (RDHAP) protocols for 9 months, which did not improve her condition. Finally, a PET scan revealed that the lesion was limited to the lung with no visible metastases or lymph node involvement, and radical surgery was performed to excise the tumor. A new IHC panel was ordered because of the conflicting reports, and it showed matching results to the first diagnosis, except for a negative CD20 result, which was attributed to rituximab in the patient's chemotherapy. A 2-year follow-up revealed no lesions or recurrence.</div></div><div><h3>Conclusion</h3><div>DLBCL is an uncommon cause for primary lung lymphomas, but high clinical suspicion must be maintained when assessing such tumors, even among younger individuals. More studies should be done to investigate the best treatment option for the anaplastic variant of DLBCL.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"17 ","pages":"Article 100362"},"PeriodicalIF":0.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143620075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-01DOI: 10.1016/j.cpccr.2025.100358
David Ibsen Dadash-Khanlou , Hanne Rønning , Helga Fibiger Munch-Petersen , Ida Lolle , Sandra Duvnjak , Bodil Elisabeth Engelmann , Elisabeth Ida Specht Stovgaard
Angiosarcoma is a rare aggressive tumor of the endothelial cells, that in its secondary form can be seen in breast cancer patients 5–10 years following radiation therapy or radical mastectomy with chronic lymphedema. In this article, we report a rare case of a breast cancer patient developing possible secondary angiosarcoma following surgery while having received no subsequent radiation therapy.
A 66-year-old female presented in 2016 with invasive ductal carcinoma (IDC) and ductal carcinoma in situ (DCIS) in her right breast. She was treated with a subcutaneous mastectomy and primary reconstruction using a DIEP-flap (deep inferior epigastric perforator flap). She received postoperative adjuvant chemotherapy combined with HER2 targeted therapy, but no radiation therapy. In 2023, the patient presented with yellowish marks on the reconstructed breast and a history of trauma to the right side of her body, suggestive of hematoma. Clinical mammography and fine needle aspiration showed only reactive changes. In the following months the cutaneous changes worsened with ulceration, discoloration, and bleeding in the reconstructed breast. A core needle biopsy was taken and angiosarcoma with high malignancy grade was found.
Microscopically, the tumor was composed of malignant mesenchymal spindle cells in a hypercellular and slit-like pattern with numerous mitotic figures and nuclear pleomorphism with oval and enlarged nucleoli. Immunohistochemical stain was strongly positive of CD34, CD31 and, remarkably, c-Myc. There was no expression of D240, cytokeratin or S-100.
The case highlights that angiosarcoma cannot be excluded in patients following extensive surgery and that we must be aware of this risk in the future.
{"title":"Possible secondary angiosarcoma following subcutaneous mastectomy with primary reconstruction without subsequent radiotherapy: A case report and literature review","authors":"David Ibsen Dadash-Khanlou , Hanne Rønning , Helga Fibiger Munch-Petersen , Ida Lolle , Sandra Duvnjak , Bodil Elisabeth Engelmann , Elisabeth Ida Specht Stovgaard","doi":"10.1016/j.cpccr.2025.100358","DOIUrl":"10.1016/j.cpccr.2025.100358","url":null,"abstract":"<div><div>Angiosarcoma is a rare aggressive tumor of the endothelial cells, that in its secondary form can be seen in breast cancer patients 5–10 years following radiation therapy or radical mastectomy with chronic lymphedema. In this article, we report a rare case of a breast cancer patient developing possible secondary angiosarcoma following surgery while having received no subsequent radiation therapy.</div><div>A 66-year-old female presented in 2016 with invasive ductal carcinoma (IDC) and ductal carcinoma in situ (DCIS) in her right breast. She was treated with a subcutaneous mastectomy and primary reconstruction using a DIEP-flap (deep inferior epigastric perforator flap). She received postoperative adjuvant chemotherapy combined with HER2 targeted therapy, but no radiation therapy. In 2023, the patient presented with yellowish marks on the reconstructed breast and a history of trauma to the right side of her body, suggestive of hematoma. Clinical mammography and fine needle aspiration showed only reactive changes. In the following months the cutaneous changes worsened with ulceration, discoloration, and bleeding in the reconstructed breast. A core needle biopsy was taken and angiosarcoma with high malignancy grade was found.</div><div>Microscopically, the tumor was composed of malignant mesenchymal spindle cells in a hypercellular and slit-like pattern with numerous mitotic figures and nuclear pleomorphism with oval and enlarged nucleoli. Immunohistochemical stain was strongly positive of CD34, CD31 and, remarkably, c-Myc. There was no expression of D240, cytokeratin or S-100.</div><div>The case highlights that angiosarcoma cannot be excluded in patients following extensive surgery and that we must be aware of this risk in the future.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"17 ","pages":"Article 100358"},"PeriodicalIF":0.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143600763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-01DOI: 10.1016/j.cpccr.2025.100361
Chen Fan , Linhui Fang , Li Yang , Fan Wang
Background
Primary Squamous Cell Carcinoma (SCC) of the breast, a rare subtype of metaplastic carcinoma, is estimated to occur in <0.1 % of breast cancer cases. In clinical practice, the coexistence of primary SCC with Invasive Ductal Carcinoma (IDC) is exceptionally rare, presenting unique challenges in diagnosis and management.
Case report
We report a patient with primary SCC complicated with IDC of the breast. This patient underwent operation, adjuvant chemotherapy and endocrine therapy according to the Breast Cancer Guidelines.
Conclusion
Primary SCC of the breast is recognized for its highly aggressive nature and resistance to treatment, often associated with a poor prognosis. Currently, there are no specific guidelines dedicated to the management of primary SCC of the breast. When primary SCC coexists with IDC of the breast, the prognosis becomes even more uncertain due to the complex interplay between these two distinct pathological entities. In this case, we have adopted a treatment strategy targeting the IDC component, following established guidelines for breast cancer management. We anticipate that this approach will contribute to a favorable prognosis for the patient.
{"title":"Primary squamous cell carcinoma complicated with invasive ductal carcinoma of breast","authors":"Chen Fan , Linhui Fang , Li Yang , Fan Wang","doi":"10.1016/j.cpccr.2025.100361","DOIUrl":"10.1016/j.cpccr.2025.100361","url":null,"abstract":"<div><h3>Background</h3><div>Primary Squamous Cell Carcinoma (SCC) of the breast, a rare subtype of metaplastic carcinoma, is estimated to occur in <0.1 % of breast cancer cases. In clinical practice, the coexistence of primary SCC with Invasive Ductal Carcinoma (IDC) is exceptionally rare, presenting unique challenges in diagnosis and management.</div></div><div><h3>Case report</h3><div>We report a patient with primary SCC complicated with IDC of the breast. This patient underwent operation, adjuvant chemotherapy and endocrine therapy according to the Breast Cancer Guidelines.</div></div><div><h3>Conclusion</h3><div>Primary SCC of the breast is recognized for its highly aggressive nature and resistance to treatment, often associated with a poor prognosis. Currently, there are no specific guidelines dedicated to the management of primary SCC of the breast. When primary SCC coexists with IDC of the breast, the prognosis becomes even more uncertain due to the complex interplay between these two distinct pathological entities. In this case, we have adopted a treatment strategy targeting the IDC component, following established guidelines for breast cancer management. We anticipate that this approach will contribute to a favorable prognosis for the patient.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"17 ","pages":"Article 100361"},"PeriodicalIF":0.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143577467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-19DOI: 10.1016/j.cpccr.2025.100357
Farzad Allameh , Afshin Moradi , Azadeh Rakhshan , Sina Samenezhad , Amir Alinejad Khorram
Muscle-invasive bladder cancer management often involves radical cystectomy, but bladder preservation protocols have gained recognition as a low-morbidity alternative for the management of carefully selected patients. However, close follow-up is crucial for prompt diagnosis of cancer recurrence. We report a case of muscle-invasive bladder cancer managed using a bladder preservation approach. Although cystoscopy and random biopsy findings appeared unremarkable during follow-up, tumor recurrence occurred in the muscular propria without involving the bladder mucosa. This case underscores the importance of revising follow-up protocols to ensure optimal patient care.
{"title":"Unanticipated recurrence of muscle-invasive bladder cancer: A case report","authors":"Farzad Allameh , Afshin Moradi , Azadeh Rakhshan , Sina Samenezhad , Amir Alinejad Khorram","doi":"10.1016/j.cpccr.2025.100357","DOIUrl":"10.1016/j.cpccr.2025.100357","url":null,"abstract":"<div><div>Muscle-invasive bladder cancer management often involves radical cystectomy, but bladder preservation protocols have gained recognition as a low-morbidity alternative for the management of carefully selected patients. However, close follow-up is crucial for prompt diagnosis of cancer recurrence. We report a case of muscle-invasive bladder cancer managed using a bladder preservation approach. Although cystoscopy and random biopsy findings appeared unremarkable during follow-up, tumor recurrence occurred in the muscular propria without involving the bladder mucosa. This case underscores the importance of revising follow-up protocols to ensure optimal patient care.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"17 ","pages":"Article 100357"},"PeriodicalIF":0.2,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143487377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mesonephric-like adenocarcinoma of the ovary is an exceedingly rare malignant tumor within the reproductive system, accounting for fewer than 1 % of all malignant tumors in women. Originating from remnants of the regressed Wolffian duct during embryonic development, its clinical manifestations are nonspecific, and its rarity often leads to delayed diagnosis, resulting in heightened morbidity and long-term recurrence. We discuss a case of 57-year-old woman with ovarian cysts that were incidentally found in abdominal and pelvic sonography and final diagnosis of mesonephric-like adenocarcinoma with peritoneal involvement and 2014 FIGO stage classification of stage IIIc which is extremely rare stage at presentation in this particular tumor. Diagnosis primarily relies on meticulous physical examination coupled with imaging, complemented by histological analysis and the tracking of diagnostic immunohistochemical markers (positive for TTF1, GATA3, PAX8, and CD10 while conversely negative for ER and PR). This study elucidates the clinical and pathophysiological attributes, diagnostic findings, and treatment strategies through the analysis of a subset of patients diagnosed with mesonephric-like adenocarcinoma in the ovary, followed by a comprehensive literature review.
{"title":"Mesonephric-like adenocarcinoma of the ovary: A rare case report and review of the literature","authors":"Maryam Hosseinirad , Elham Mirzaeian , Amirhossein Charejoo","doi":"10.1016/j.cpccr.2025.100355","DOIUrl":"10.1016/j.cpccr.2025.100355","url":null,"abstract":"<div><div>Mesonephric-like adenocarcinoma of the ovary is an exceedingly rare malignant tumor within the reproductive system, accounting for fewer than 1 % of all malignant tumors in women. Originating from remnants of the regressed Wolffian duct during embryonic development, its clinical manifestations are nonspecific, and its rarity often leads to delayed diagnosis, resulting in heightened morbidity and long-term recurrence. We discuss a case of 57-year-old woman with ovarian cysts that were incidentally found in abdominal and pelvic sonography and final diagnosis of mesonephric-like adenocarcinoma with peritoneal involvement and 2014 FIGO stage classification of stage IIIc which is extremely rare stage at presentation in this particular tumor. Diagnosis primarily relies on meticulous physical examination coupled with imaging, complemented by histological analysis and the tracking of diagnostic immunohistochemical markers (positive for TTF1, GATA3, PAX8, and CD10 while conversely negative for ER and PR). This study elucidates the clinical and pathophysiological attributes, diagnostic findings, and treatment strategies through the analysis of a subset of patients diagnosed with mesonephric-like adenocarcinoma in the ovary, followed by a comprehensive literature review.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"17 ","pages":"Article 100355"},"PeriodicalIF":0.2,"publicationDate":"2025-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143422162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
We describe the case of a 81-year-old male patient with Cardiac device-related endocarditis caused by Streptococcus gallolyticus (Sgg) and colonic adenocarcinoma with fatal neurological complications. It is important to highlight the need for thorough colon examination, even in asymptomatic individuals, when diagnosing infective endocarditis caused by Sgg.
{"title":"Streptococcus gallolyticus endocarditis, a silent sign for colonic cancer: Case report and literature review","authors":"Youssef Lahmouz, Zaynab Mouhib, Najat Mouine, Hicham Bouzelmat, Ali Chaib, Aatif Benyass","doi":"10.1016/j.cpccr.2025.100354","DOIUrl":"10.1016/j.cpccr.2025.100354","url":null,"abstract":"<div><div>We describe the case of a 81-year-old male patient with Cardiac device-related endocarditis caused by Streptococcus gallolyticus (Sgg) and colonic adenocarcinoma with fatal neurological complications. It is important to highlight the need for thorough colon examination, even in asymptomatic individuals, when diagnosing infective endocarditis caused by Sgg.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"17 ","pages":"Article 100354"},"PeriodicalIF":0.2,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143394930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-06DOI: 10.1016/j.cpccr.2025.100356
Dr. Mitali M․ Rath , Dr. Rashmi Patnayak , Dr. Shiva Dhala Mohapatra , Dr. Prakash Chandra Dalei
Introduction
Neuroendocrine neoplasms (NENs) of the gastrointestinal (GI) tract or pancreas are collectively called Gastroenteropancreatic NENs (GEP-NENs). The incidence and prevalence of these tumors is on a rise, owing to higher awareness and advanced diagnostic modalities. Many of them are incidentally detected during endoscopy or cross-sectional imaging. Here we present nine cases of GEP-NENs which were detected incidentally during their hospital visit for various GI complaints.
Method
Upper GI endoscopic biopsy was performed in 1052 patients at this single institution. Routine histopathology, and when needed, immunohistochemistry (IHC) tests were carried out. Final diagnosis of NEN was made on the basis of the 2019 WHO classification.
Result
Nine cases were histologically confirmed having NEN. The lesions were located in the duodenum in six cases and in the stomach in three. All except one were Grade 1 neuroendocrine tumors (NET), one patient had grade 2 NET. In three cases the NET was limited to mucosa and submucosal invasion was seen in six cases. Patients were managed with polypectomy(n = 2), endoscopic mucosal resection (EMR)(n = 2), endoscopic submucosal dissection (ESD)(n = 3), surgical resection(n = 1) and no therapeutic intervention, only regular follow up (n = 1)
Discussion
All polypoidal or submucosal lesions of the GI tract may be biopsied to avoid missing out GEP-NENs. New and advanced techniques of GI endoscopy play a pivotal role in diagnosis and management of GEP-NENs. Here we are sharing our experience of upper GI tract NENs at a single gastroenterology super speciality centre in Eastern India.
{"title":"Incidental encounters – unveiling neuroendocrine neoplasms in routine upper gastrointestinal endoscopy: A case series","authors":"Dr. Mitali M․ Rath , Dr. Rashmi Patnayak , Dr. Shiva Dhala Mohapatra , Dr. Prakash Chandra Dalei","doi":"10.1016/j.cpccr.2025.100356","DOIUrl":"10.1016/j.cpccr.2025.100356","url":null,"abstract":"<div><h3>Introduction</h3><div>Neuroendocrine neoplasms (NENs) of the gastrointestinal (GI) tract or pancreas are collectively called Gastroenteropancreatic NENs (GEP-NENs). The incidence and prevalence of these tumors is on a rise, owing to higher awareness and advanced diagnostic modalities. Many of them are incidentally detected during endoscopy or cross-sectional imaging. Here we present nine cases of GEP-NENs which were detected incidentally during their hospital visit for various GI complaints.</div></div><div><h3>Method</h3><div>Upper GI endoscopic biopsy was performed in 1052 patients at this single institution. Routine histopathology, and when needed, immunohistochemistry (IHC) tests were carried out. Final diagnosis of NEN was made on the basis of the 2019 WHO classification.</div></div><div><h3>Result</h3><div>Nine cases were histologically confirmed having NEN. The lesions were located in the duodenum in six cases and in the stomach in three. All except one were Grade 1 neuroendocrine tumors (NET), one patient had grade 2 NET. In three cases the NET was limited to mucosa and submucosal invasion was seen in six cases. Patients were managed with polypectomy(<em>n</em> = 2), endoscopic mucosal resection (EMR)(<em>n</em> = 2), endoscopic submucosal dissection (ESD)(<em>n</em> = 3), surgical resection(<em>n</em> = 1) and no therapeutic intervention, only regular follow up (<em>n</em> = 1)</div></div><div><h3>Discussion</h3><div>All polypoidal or submucosal lesions of the GI tract may be biopsied to avoid missing out GEP-NENs. New and advanced techniques of GI endoscopy play a pivotal role in diagnosis and management of GEP-NENs. Here we are sharing our experience of upper GI tract NENs at a single gastroenterology super speciality centre in Eastern India.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"17 ","pages":"Article 100356"},"PeriodicalIF":0.2,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143386582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-26DOI: 10.1016/j.cpccr.2025.100352
John S. Howard , Trisha Wise-Draper , Kevin Redmond , Rebecca Howell , Steven D. Gilday , Dustin A. Silverman
Merkel cell carcinoma (MCC) is an aggressive neuroendocrine tumor of the skin, most commonly affecting sun exposed areas of the head and neck in older patients. Surgery remains the mainstay of treatment followed by adjuvant radiation or chemoradiation therapy in appropriately selected patients. Though MCC is associated with high rates of locoregional recurrence and propensity for distant metastases, metastatic disease involving the oropharynx is exceedingly rare; the optimal therapeutic approach in this setting remains controversial. Herein, we report a rare case of metastatic MCC to the base of tongue presenting as acute oropharyngeal hemorrhage in an 86-year-old male without an identifiable primary lesion. Definitive airway management and treatment with tumor-directed radiation and concurrent pembrolizumab were successful in this case. Optimal diagnostic and treatment strategies are discussed in addition to a review of the literature for patients with metastatic MCC affecting the oropharynx. Further, the role of transoral robotic surgery (TORS), systemic chemotherapeutic regimens, and immunotherapy in this setting are highlighted.
{"title":"Oropharyngeal metastasis of merkel cell carcinoma: Case report and review of the literature","authors":"John S. Howard , Trisha Wise-Draper , Kevin Redmond , Rebecca Howell , Steven D. Gilday , Dustin A. Silverman","doi":"10.1016/j.cpccr.2025.100352","DOIUrl":"10.1016/j.cpccr.2025.100352","url":null,"abstract":"<div><div>Merkel cell carcinoma (MCC) is an aggressive neuroendocrine tumor of the skin, most commonly affecting sun exposed areas of the head and neck in older patients. Surgery remains the mainstay of treatment followed by adjuvant radiation or chemoradiation therapy in appropriately selected patients. Though MCC is associated with high rates of locoregional recurrence and propensity for distant metastases, metastatic disease involving the oropharynx is exceedingly rare; the optimal therapeutic approach in this setting remains controversial. Herein, we report a rare case of metastatic MCC to the base of tongue presenting as acute oropharyngeal hemorrhage in an 86-year-old male without an identifiable primary lesion. Definitive airway management and treatment with tumor-directed radiation and concurrent pembrolizumab were successful in this case. Optimal diagnostic and treatment strategies are discussed in addition to a review of the literature for patients with metastatic MCC affecting the oropharynx. Further, the role of transoral robotic surgery (TORS), systemic chemotherapeutic regimens, and immunotherapy in this setting are highlighted.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"17 ","pages":"Article 100352"},"PeriodicalIF":0.2,"publicationDate":"2025-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143154703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号